Three-Arm Comparative Study of Miglitol and Mitiglinide Alone and in Combination -Efficacy and Safety Studies- - MM study

Kawasaki Medical School0 个研究点目标入组 60 人开始时间: 2013年3月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Patients who have undergone dietary/exercise therapy of less than 8 weeks since diabetes diagnosis (2)Patients who have undergone biguanide therapy of less than 8 weeks (3)Patients who are undergoing treatment with a sulfonylurea agent (4)Patients who are undergoing treatment with a thiazolidine agent (5)Patients who are undergoing treatment with an arufa-glucosidase inhibitor (Patients who had prior treatment with voglibose or acarbose were allowed to participate in this study, provided that 8 weeks or longer have passed since the termination of the oral treatment.) (6)Patients who are undergoing treatment with a rapid-acting insulin secretagogue (Patients who had prior treatment with nateglinide were allowed to participate in this study, provided that 8 weeks or longer have passed since the termination of the oral treatment.) (7)Patients who are undergoing concomitant treatment with an arufa-glucosidase inhibitor and a rapid-acting insulin secretagogue (8)Patients who are undergoing or who require insulin treatment (9)Patients with severe ketosis or in a diabetic coma or pre-coma (10)Patients with severe infection, perioperative, severe injury (11)Patients with history of hypersensitivity to any ingredient in the study drug (12)Women who are pregnant or who may be pregnant (13)Other patients whom their physicians in charge considered unsuitable for inclusion in this study

发起方